Summit Therapeutics Inc (NASDAQ:SMMT) traded at $23.52 at close of the session on Monday, January 27 and made a downward move of -1.01% on its previous day’s price.
Looking at the stock we see that its previous close was $23.76 and the beta (5Y monthly) reads -0.923 with the day’s price range being $22.32 – $23.56. In terms of its 52-week price range, SMMT has a high of $33.89 and a low of $2.10. The company’s stock has gained about 25.98% over that past 30 days.
Summit Therapeutics Inc has a market cap of $17.34 billion and is expected to release its quarterly earnings report in February.
On the other hand, looking at the outlook for the SMMT stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Summit Therapeutics Inc (SMMT) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 20.64% off its SMA20 and 24.06% from its 50-day simple moving average. The RSI (14) is pointing at 66.05 while the volatility over the past week is 8.98% and jumps to 7.13% over the past one month. The beta value is -0.85, while the average true range (ATR) is currently pointing at 1.49. The average price target for the stock over the next 12 months is $36, with the estimates having a low of $23 and a high of $45. These price ends are 2.21% and -91.33% off the current price level respectively, although investors could be excited at the prospect of a -53.06% if the SMMT share price touches on the median price of $36.
Coming back to Summit Therapeutics Inc (NASDAQ:SMMT), we note that the average 3-month trading volume was 2.25 million, while that of the preceding 10-day period stands at 2.99 million. Current shares outstanding are 737.09 million.
The insiders hold 84.45% of the company’s shares while institutions hold 11.53%. The data shows that short shares as of 2024-12-31, stood at 19.94 million at a short ratio of 9.05. This represents a 1678.00 short interest in shares outstanding on 2024-12-31. Shares short rose in December from the previous month at 16.84 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 31.80% up in year-to-date price movement.
